SorafenibSorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. Read from the Drugbox of the Wikipedia article Sorafenib, revision 1373726418.

Property

Value

Bioavailability

43.5 %

Protein binding

99.5 %

Elimination half-life

36.5 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.